Carlyle buys Johnson & Johnson unit for $4.15bn

 Carlyle will fund the investment using capital from its $13bn Fund VI.

The Carlyle Group will acquire Johnson & Johnson’s Ortho-Clinical Diagnostics unit for $4.15 billion, according to a statement.

The division provides diagnostic and monitoring services for blood donor centres as well as chemistry and testing systems for laboratories throughout the US and in 130 countries.

Carlyle will fund the deal using capital from its Carlyle Partners Fund VI, which closed on $13 billion in November 2013. Fund VI launched in late 2011 with a $10 billion target and a $12 billion hard-cap, Private Equity International previously reported. The deal is expected to close in the middle of 2014.

“Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation,” Carlyle managing director Stephen Wise said in the statement. “We expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide”.

Carlyle has invested $6.3 billion in healthcare companies around the world. The firm’s most recent acquisition came in December 2011 when it acquired research organization Pharmaceutical Product Development. Carlyle’s healthcare group is led by managing directors Karen Bechtel and Wise.